We were proud to take part in the official launch of the 2025 Catalyser programme last Thursday at Stevenage Bioscience Catalyst!
May 19, 2025
Pharmidex is excited to support this incredible initiative, which welcomes 8 promising therapeutics companies at (or near) the pre-clinical stage.
Over the next 8 weeks, they’ll sharpen their strategy using the Triple Chasm framework and gain access to a powerful mix of scientific, business, and communication support.
During the launch, our very own
Ash Alavijeh joined
Prabhu Velusami, MD (Johnson & Johnson) and
Daniel Marshall (MSD) in a panel discussion exploring trends and opportunities in the therapeutics landscape.
It was a brilliant exchange of insights that inspired the cohort and sparked new conversations.
As part of the Catalyser package, we’re proud to offer:
🔬 Complimentary CRO services from Pharmidex
🤖 AI innovation support with Asae Biotechnology Consulting
🎤 1:1 storytelling coaching with
Kat Arney
from First Create The Media
Huge thanks to Hertfordshire Futures and Stevenage Bioscience Catalyst for driving this programme and for the opportunity to collaborate with such a forward-thinking ecosystem!


We’re excited that Ash Alavijeh (Head of Operations) and Janette Robertson (Business Development Manager) will attend the Milner Therapeutics Symposium on 30 June 2025 in Cambridge. They look forward to connecting with attendees and discussing how Pharmidex can support collaboration and innovation in drug discovery. 📍 https://milner.glueup.com/event/milner-therapeutics-symposium-2025-132179/home.html

At Pharmidex our CNS team are specialists in microdialysis, with over 30 years of experience in the technique. Our team combines the technique with powerful analytical techniques, allowing us to measure 13 different analytes in addition to test compounds in each sample. This method allows for detailed Pharmacokinetic and Pharmacodynamic profiling. 🎯 Dual probe or single probe | 🔬 Murine models | ⏳ Real-time PK/PD Ready to add this to your CNS programme? Let's talk.